FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083761008> ?p ?o ?g. }

• W3083761008 abstract "Immunotherapy targeting immune checkpoints has become a common approach for many types of cancer but currently there are no reliable biomarkers to predict and monitor treatment response. Immunohistochemical staining of PD-L1, which was initially developed as a companion diagnostic, is problematic due to tumor heterogeneity, variations in specimen preparation and multiple scoring schemes. There is, therefore, a critical need for a better biomarker to guide the use of immunotherapy to improve clinical outcomes. We previously reported that higher levels of Bim and CX3CR1/granzyme B in CD8+ T cells were associated with increased response to PD-1 blockade therapy in patients with melanoma; high levels of Bim were also prognostic of poor survival in melanoma patients. In this study, we investigated the roles of Bim and CX3CR1/granzyme B in patients receiving PD-1 blockade therapy (i.e. pembrolizumab) for small bowel adenocarcinoma as part of planned correlative analysis of the ACCRU clinical trial, NCT02949219. Patients with unresectable or metastatic biopsy-proven small bowel adenocarcinoma (excluding ampulla of Vater and appendix) who had at least one prior line of systemic chemotherapy were eligible for the trial. Pembrolizumab (200 mg) was administered over 30 minutes intravenously every 3 weeks until unacceptable toxicity, disease progression, or patient refusal. All patients underwent peripheral blood collection at baseline prior to initiation of treatment and then after 3 cycles of treatment. Levels of Bim and CX3CR1/granzyme B in circulating T cells were quantified by flow cytometry using patients9 peripheral blood mononuclear cells. Data was analyzed via Cox proportional hazards model, Wilcoxon Rank-Sum test, and Kaplan Meier curves using SAS 9.4. A total of 35 eligible patients were included in the analysis. Three patients had confirmed response (all partial responses) and 10 had stable disease as their best overall response. Seven patients had disease progression around the second blood draw. The median time from baseline to the second blood draw was 9 weeks. Lower levels of Bim in CD8+CD11ahi T cells at baseline on the percentage scale were associated with treatment response (median 54.5% vs. 79.5%; p=0.0087) and disease control (partial response plus stable disease; median 71.2% vs. 81.3%; p=0.0104) but higher levels led to worse progression-free survival (hazard ratio=1.05, 95% confidence interval 1.01-1.08; p=0.0051). In addition, positive changes in CX3CR1/granzyme B in CD8+CD11ahi T cells from baseline were associated with better overall survival (median 20.2 months vs. 3.7 months, p=0.0086). The levels of PD-1 and Ki-67 in CD8+CD11ahi T cells were not associated with treatment response or survival. In conclusion, Bim and CX3CR1/granzyme B are biomarkers that associate with response and survival benefits respectively of PD-1 blockade therapy. This preliminary data calls for a larger-scale, prospective study to validate their predictive and prognostic utilities. Citation Format: Mojun Zhu, Henan Zhang, Nathan R. Foster, Haidong Dong, Tanios S. Bekaii-Saab, Brandy L. Jaszewski, Patrick M. Boland, Michael J. Overman, Katrina Pedersen, Robert R. McWilliams, Academic and Community Cancer Research United (AACRU). Bim and CX3CR1/granzyme B in circulating CD8+ T cells are predictive biomarkers for PD-1 blockade therapy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4467." @default.
• W3083761008 created "2020-09-11" @default.
• W3083761008 creator A5001261934 @default.
• W3083761008 creator A5003827387 @default.
• W3083761008 creator A5006194799 @default.
• W3083761008 creator A5008026182 @default.
• W3083761008 creator A5038413156 @default.
• W3083761008 creator A5043260959 @default.
• W3083761008 creator A5045259827 @default.
• W3083761008 creator A5049144598 @default.
• W3083761008 creator A5069585958 @default.
• W3083761008 creator A5074046772 @default.
• W3083761008 creator A5074891676 @default.
• W3083761008 date "2020-08-13" @default.
• W3083761008 modified "2023-10-14" @default.
• W3083761008 title "Abstract 4467: Bim and CX3CR1/granzyme B in circulating CD8+ T cells are predictive biomarkers for PD-1 blockade therapy" @default.
• W3083761008 doi "https://doi.org/10.1158/1538-7445.am2020-4467" @default.
• W3083761008 hasPublicationYear "2020" @default.
• W3083761008 type Work @default.
• W3083761008 sameAs 3083761008 @default.
• W3083761008 citedByCount "1" @default.
• W3083761008 countsByYear W30837610082021 @default.
• W3083761008 crossrefType "proceedings-article" @default.
• W3083761008 hasAuthorship W3083761008A5001261934 @default.
• W3083761008 hasAuthorship W3083761008A5003827387 @default.
• W3083761008 hasAuthorship W3083761008A5006194799 @default.
• W3083761008 hasAuthorship W3083761008A5008026182 @default.
• W3083761008 hasAuthorship W3083761008A5038413156 @default.
• W3083761008 hasAuthorship W3083761008A5043260959 @default.
• W3083761008 hasAuthorship W3083761008A5045259827 @default.
• W3083761008 hasAuthorship W3083761008A5049144598 @default.
• W3083761008 hasAuthorship W3083761008A5069585958 @default.
• W3083761008 hasAuthorship W3083761008A5074046772 @default.
• W3083761008 hasAuthorship W3083761008A5074891676 @default.
• W3083761008 hasConcept C126322002 @default.
• W3083761008 hasConcept C154317977 @default.
• W3083761008 hasConcept C167672396 @default.
• W3083761008 hasConcept C170493617 @default.
• W3083761008 hasConcept C185592680 @default.
• W3083761008 hasConcept C202751555 @default.
• W3083761008 hasConcept C203014093 @default.
• W3083761008 hasConcept C2778468042 @default.
• W3083761008 hasConcept C2779968557 @default.
• W3083761008 hasConcept C2780380082 @default.
• W3083761008 hasConcept C502942594 @default.
• W3083761008 hasConcept C55493867 @default.
• W3083761008 hasConcept C71924100 @default.
• W3083761008 hasConcept C8891405 @default.
• W3083761008 hasConceptScore W3083761008C126322002 @default.
• W3083761008 hasConceptScore W3083761008C154317977 @default.
• W3083761008 hasConceptScore W3083761008C167672396 @default.
• W3083761008 hasConceptScore W3083761008C170493617 @default.
• W3083761008 hasConceptScore W3083761008C185592680 @default.
• W3083761008 hasConceptScore W3083761008C202751555 @default.
• W3083761008 hasConceptScore W3083761008C203014093 @default.
• W3083761008 hasConceptScore W3083761008C2778468042 @default.
• W3083761008 hasConceptScore W3083761008C2779968557 @default.
• W3083761008 hasConceptScore W3083761008C2780380082 @default.
• W3083761008 hasConceptScore W3083761008C502942594 @default.
• W3083761008 hasConceptScore W3083761008C55493867 @default.
• W3083761008 hasConceptScore W3083761008C71924100 @default.
• W3083761008 hasConceptScore W3083761008C8891405 @default.
• W3083761008 hasLocation W30837610081 @default.
• W3083761008 hasOpenAccess W3083761008 @default.
• W3083761008 hasPrimaryLocation W30837610081 @default.
• W3083761008 hasRelatedWork W192985935 @default.
• W3083761008 hasRelatedWork W1969504080 @default.
• W3083761008 hasRelatedWork W2002305598 @default.
• W3083761008 hasRelatedWork W2017949628 @default.
• W3083761008 hasRelatedWork W2058581379 @default.
• W3083761008 hasRelatedWork W2153336777 @default.
• W3083761008 hasRelatedWork W2404956728 @default.
• W3083761008 hasRelatedWork W2925226289 @default.
• W3083761008 hasRelatedWork W3205830276 @default.
• W3083761008 hasRelatedWork W4200379672 @default.
• W3083761008 isParatext "false" @default.
• W3083761008 isRetracted "false" @default.
• W3083761008 magId "3083761008" @default.
• W3083761008 workType "article" @default.